[1]中华心血管病杂志编委会血脂异常防治对策专题组.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175.
[2]中国胆固醇教育计划血脂异常防治建议专家组,中华心血管病杂志编辑委员会,血脂与动脉粥样硬化循证工作组,等.2014年中国胆固醇教育计划血脂异常防治专家建议[J].中华心血管病杂志,2014,42(8):633-636.DOI:10.3760/cma.j.issn.0253-3758.2014.08.003.
[3]郭远林,李建军.中国成人血脂异常防治指南(2016年修订版)亮点解读[J].中国医学前沿杂志(电子版),2017,9(6):12-14.
[4]武阳丰,赵冬,周北凡,等.中国成人血脂异常诊断和危险分层方案的研究[J].中华心血管病杂志,2007,35(5):428-433.DOI:10.3760/j.issn:0253-3758.2007.05.005.
WU Y F,ZHAO D,ZHOU B F,et al.Cut offs and risk stratification of dyslipidemia in Chinese adults[J].Chinese Journal of Cardiology,2007,35(5):428-433.DOI:10.3760/j.issn:0253-3758.2007.05.005.
[5]RAY K K,KASTELEIN J J P,BOEKHOLDT S M,et al.The ACC/AHA 2013 Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults:the good the bad and the uncertain:a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011[J].Eur Heart J,2014,35(15):960-968.DOI:10.1093/eurheartj/ehu107.
[6]李剑虹,王丽敏,米生权,等.2010年我国成年人血脂异常知晓率和治疗率及控制率调查[J].中华预防医学杂志,2012,46(8):687-691.DOI:10.3760/cma.j.issn.0253-9624.2012.08.004.
LI J H,WANG L M,MI S Q,et al.Awareness rate,treatment rate and control rate of dyslipidemia in Chinese adults,2010[J].Chinese Journal of Preventive Medicine,2012,46(8):687-691.DOI:10.3760/cma.j.issn.0253-9624.2012.08.004.
[7]赵水平,黄贤圣,胡大一.比较ACC/AHA与ESC/EAS血脂指南[J].中华心血管病杂志,2014,42(11):898-899.DOI:10.3760/cma.j.issn.0253-3758.2014.11.004.
[8]BAIGENT C,LANDRAY M J,REITH C,et al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease(Study of Heart and Renal Protection):a randomised placebo-controlled trial[J].Lancet,2011,377(9784):2181-2192.DOI:10.1016/S0140-6736(11)60739-3.